Clinical trials: Patients With Tumor
Colorectal Carcinoma
Patients With Rectal Cancer: a "Wait-and-see" Approach
Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiotherapy to a dose of 45Gy in 25 fractions with a tumor boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary…
- Trial name
- NCT03001362
- Testing
- Radical external beam radiotherapy
- Where
- 2 sites in Canada
- Volunteers
- 48 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Multiple Myeloma
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation…
- Trial name
- NCT06932562
- Testing
- Linvoseltamab, Daratumumab, Lenalidomide
- Where
- 59 sites in Australia, Austria and 16 more
- Volunteers
- 1,000 people
- Sponsor
- European Myeloma Network B.V.
Advanced/Metastatic Hepatocellular Carcinoma
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
This is a single arm and open-label phase I trial to evaluate the safety, tolerability and efficacy of the oncolytic virus M1 （M1-c6v1）(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each 28 day cycle) combined with anti-PD-1…
- Trial name
- NCT04665362
- Testing
- Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
- Volunteers
- 10 people
- Sponsor
- Liang Peng
Multiple Myeloma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well…
- Trial name
- DFCI 10-106 (NCT01208662)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 46 sites in United States
- Volunteers
- 729 people
- Sponsor
- Paul Richardson, MD
Lung Cancer
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00798603
- Testing
- bevacizumab, carboplatin, pemetrexed disodium
- Where
- 217 sites in United States
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
LiverMultiScan Analysis of MRI Scans in HCC
This project is a pilot study to interrogate the potential of LMS as a predictive tool for the selection of therapy for HCC patients.
- Trial name
- NCT04451603
- Testing
- Surgery, Radiation therapy, Drug treatment
- Where
- Singapore
- Volunteers
- 21 people
- Sponsor
- National Cancer Centre, Singapore
Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
VAH vs VA in Newly Diagnosed Elderly AML
This is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and…
- Trial name
- NCT07469046
- Testing
- Venetoclax, Azacitidine, Homoharringtonine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
COVID-19 Infection, Cancer Patients
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the…
- Conditions
- COVID-19 Infection, Cancer Patients, General Population
- Trial name
- FALP-COVID (NCT04384588)
- Testing
- Convalescent Plasma from COVID-19 donors
- Where
- Chile
- Volunteers
- 100 people
- Sponsor
- Fundacion Arturo Lopez Perez
Cancer of Kidney, Kidney Cancer
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
- Conditions
- Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney
- Trial name
- NCT00199888
- Testing
- 124-Iodine-cG250 (124I-cG250)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ludwig Institute for Cancer Research
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Depression, Neurotoxicity
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease…
- Conditions
- Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00069927
- Testing
- Adderall-XR®, Concerta®
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Lymphoma, Follicular Lymphoma
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
- Conditions
- Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
- Trial name
- NCT06510361
- Testing
- Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Beth Israel Deaconess Medical Center
Colorectal Cancer (Diagnosis), Malnutrition or Risk of Malnutrition
Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial
This clinical study aims to evaluate whether short-term personalized nutritional support, when combined with structured health education, can improve nutritional status, quality of life, and clinical outcomes in patients who have…
- Trial name
- NUTRI-CRC (NCT07087561)
- Testing
- Personalized Oral Nutritional Supplementation, Personalized Parenteral Nutritional Supplementation, Structured Nutrition-Focused Health Education
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xiaoqin Luo
Advanced Cancer
A Dose-Escalation Study for Patients With Advanced Cancer
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
- Trial name
- NCT01214642
- Testing
- pegfilgrastim, LY2523355
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Chemotherapy of NSCLC With or Without Icotinib
Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitors (EGFR-TKI) confers a…
- Trial name
- NCT02430974
- Testing
- Icotinib
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pancreatic Cancer
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy.
- Trial name
- NCT07784374
- Testing
- GFH375, GFH276, GFS202A
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Recurrent Glioblastoma, Recurrent Gliosarcoma
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent).
- Trial name
- NCT05017610
- Testing
- Liothyronine, Lomustine, Methimazole
- Sponsor
- Emory University
Cancer, Elderly
Optimization and Improvement of Care Course for 75 Years and Over Patient With Cancer and Living in Nursing Home on the Marseille Agglomeration
According to data from the French National Cancer Institute (INCA), almost one third of the cancers were diagnosed in overs 75 years patients in France in 2008.
- Trial name
- ONCO-EHPAD (NCT03103659)
- Testing
- personalised care plan
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Advanced Cancer, Metastatic Cancer
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered…
- Trial name
- PROOF (NCT06963723)
- Testing
- Financial Hardship Screening, Enhanced Usual Care
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 1,000 people
- Sponsor
- Alliance Foundation Trials, LLC.
Triple Negative Breast Cancer
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast…
- Trial name
- DIAMOND (NCT06954480)
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Durvalumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Queen Mary University of London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.